A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT01585805

Title field or adapter rule

{'original_value': 'A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:26.045670+00:00

Published At

2026-05-19T00:00:00+00:00

Record Updated At

2026-09-11

Results Posted At

2026-05-19

Source Retrieved At

2026-10-31T22:17:56.788771+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-09-11", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT01585805"

protocolSection.identificationModule.officialTitle

"A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2026-05-19", "type": "ACTUAL"}

Study condition terms

• Locally Advanced Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Stage III Pancreatic Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Stage IV Pancreatic Cancer AJCC v8 (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Arm A (veliparib, gemcitabine hydrochloride, cisplatin)', 'Arm B (gemcitabine hydrochloride, cisplatin)'], 'description': 'Undergo biopsy', 'name': 'Biopsy Procedure', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm A (veliparib, gemcitabine hydrochloride, cisplatin)', 'Arm B (gemcitabine hydrochloride, cisplatin)', 'Arm C (veliparib)'], 'description': 'Undergo tumor tissue and blood sample collection', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm A (veliparib, gemcitabine hydrochloride, cisplatin)', 'Arm B (gemcitabine hydrochloride, cisplatin)', 'Part I (veliparib, gemcitabine, cisplatin)'], 'description': 'Given IV', 'name': 'Cisplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm A (veliparib, gemcitabine hydrochloride, cisplatin)', 'Arm B (gemcitabine hydrochloride, cisplatin)', 'Arm C (veliparib)'], 'description': 'Undergo CT', 'name': 'Computed Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm A (veliparib, gemcitabine hydrochloride, cisplatin)', 'Arm B (gemcitabine hydrochloride, cisplatin)', 'Part I (veliparib, gemcitabine, cisplatin)'], 'description': 'Given IV', 'name': 'Gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm A (veliparib, gemcitabine hydrochloride, cisplatin)', 'Arm B (gemcitabine hydrochloride, cisplatin)', 'Part I (veliparib, gemcitabine, cisplatin)'], 'description': 'Given IV', 'name': 'Gemcitabine Hydrochloride', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm A (veliparib, gemcitabine hydrochloride, cisplatin)', 'Arm B (gemcitabine hydrochloride, cisplatin)', 'Arm C (veliparib)'], 'description': 'Undergo MRI', 'name': 'Magnetic Resonance Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm A (veliparib, gemcitabine hydrochloride, cisplatin)', 'Arm C (veliparib)', 'Part I (veliparib, gemcitabine, cisplatin)'], 'description': 'Given PO', 'name': 'Veliparib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Cisplatin (protocolSection.armsInterventionsModule.interventions[].name)
• Gemcitabine (protocolSection.armsInterventionsModule.interventions[].name)
• Gemcitabine Hydrochloride (protocolSection.armsInterventionsModule.interventions[].name)
• Veliparib (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.